Home > Neurology > MS Virtual 2020 > Novel Treatment Directions > Masitinib: a first-in-class TKI as treatment of progressive MS

Masitinib: a first-in-class TKI as treatment of progressive MS


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
AB07002
Results of a randomised phase 3 trial indicate that masitinib may be a new treatment option for both primary progressive MS and non-active secondary progressive MS [1]. Treatment with this tyrosine kinase inhibitor (TKI) resulted in a significant and sustained change in EDSS score over 2 years. Masitinib has a novel mechanism of action which is thought to have an impact on the innate immune system by selectively inhibiting mast cell activity (measured by c-KIT, LYN, and FYN) and microglia activity (measured by CSF1R). Results of a randomised, double-blind, placebo-controlled, phase 2b/3 trial were presented. The trial had novel design features, evaluating 2 independent parallel groups: 4.5 mg/kg/day versus matched placebo, and titrated 6.0 mg/kg/day versus placebo. Efficacy results from the high-dose parallel grou...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on